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assisted laser desorption/ionization
(MALDI)-TOF MS, with its higher
resolution, is the capability of SELDI
to enrich low-abundance proteins
from complex matrices such as
plasma, through, for example, the
coupling of specific antibodies to the
chip surfaces (4 ). Such an approach
is an important methodologic aspect
in “second phase” proteomics, which
are characterized by repetitive investigation of the same protein to validate the protein phenotype in large
population-based studies. This provides a basis for diagnostic progress
in personalized medicine (5 ). For
TTR, such an approach is relevant
not only in the diagnosis of TTRrelated amyloidosis but also in other
diseases.
The true problem with on-chip immunopurification is not the resolution of the MS, which can be solved
by use of specific available interfaces,
but the efficient coupling of the antibody to the chip surface. When an
on-chip immunoassay format is being used, it is important that the
protein chip retains the antibody in
an active state at high density. Results are greatly affected by functionality characteristics, such as the stability, affinity, and specificity of the
antibody. On the basis of studies
relating to microarrays, only 5%–20%
of commercially available antibodies
are suitable for one or the other microarray format (6 ).
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lar material in borderline or difficult
cases (5–7 ). The US Food and Drug
Administration (FDA) has recently
cleared a hybrid capture-based system (HCII; Digene) for screening
women over 30 years of age as an
adjunct to Pap testing (8 ). Researchers have developed consensus primers for the detection of HPV DNA by
PCR (9, 10 ). We developed and evaluated a multiplex PCR for the simultaneous detection of HPV and C.
trachomatis from PreservCytTM (ThinPrep) solution.
The multiplex PCR was performed
on 100 cervical PreservCyt fluid
specimens collected from women attending their general practitioners
for routine cervical screening. We
used the MY09/11 primers (9 ) for
HPV and plasmid primers for C. trachomatis (11 ), which generated fragments of 450 and 201 bp, respectively. Primers for the human
␤-globin gene were included in the
multiplex as an internal DNA amplification control, generating a 110-bp
product (12 ) (see Fig. 1 in the Data
Supplement that accompanies the
online version of this Letter at http://
www.clinchem.org/content/vol51/
issue7/). The PCR mixture contained
5 pmol of each of the forward and
reverse primers of the MY09/11 and
CTP1/2 primer sets and 10 pmol of
each of the forward and reverse
primers of the PCO3/4 primer set,
200 M deoxynucleoside triphosphates, 10⫻ PCR buffer [containing
10 mM Tris-HCl (pH 8.3), 50 mM
KCl], 2 mM MgCl2, and 1 U of Platinum Taq DNA polymerase (Invitrogen Ltd.) in a final volume of 20 L.
The PCR was initiated by a 10-min
denaturation and enzyme activation
step at 95 °C and was completed by a
10-min extension step at 72 °C. The
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Validation of a Multiplex PCR Assay
for the Simultaneous Detection of
Human Papillomavirus and Chlamydia
trachomatis in Cervical PreservCyt
Samples

To the Editor:
Chlamydia trachomatis is the most
common sexually transmitted bacterium worldwide (1 ) and a leading
cause of infertility in women (2 ).
Human papillomaviruses (HPVs) are
the most important single agent
causing carcinoma of the uterine cervix (3 ). Combined molecular screening for C. trachomatis and HPV could
be justified given their propensity to
cause asymptomatic infections, particularly in high-risk groups. Features of HPV infection of cells of the
uterine cervix are traditionally reported by the Pap smear method (4 ).
The introduction of liquid-based cytology, such as the ThinPrep® Pap
TestTM, has had the effect of improving the sensitivity of conventional
cytologic screening with the potential for HPV testing of residual cellu-

Table 1. Comparison of multiplex and single PCR for the detection of HPV and C.
trachomatis in PreservCyt cervical samples.
Multiplex positive, n
Sample cohort

MY09/11

GP clinic (n ⫽ 100)
GUM clinic (n ⫽ 34)

21
10

c

a

a

CTP1/2

2
34

Single PCR positive, n
b

MY09/11

GP5ⴙ/6ⴙa

CTP1/2

Hsp60b

24
10

14
10

2
34

2
34

Primers for the detection of HPV.
Primers for the detection of C. trachomatis.
c
Women who attended general practitioner (GP) clinics for routine cervical screening.
b

1302

temperature cycles were as follows:
40 cycles of 30 s at 95 °C, 1 min at
57 °C, and 1 min at 72 °C.
The detection limit was estimated
on serial dilutions, from 108 to 101
copies/L, of cloned HPV MY09/11
and the C. trachomatis CTP PCR
product in the pCR® 2.1-TOPO® (Invitrogen Ltd). To evaluate the sensitivity and specificity of the multiplex
PCR for the detection of each organism, we performed single PCRs on
all samples: one PCR that detects
HPV by use of the GP5⫹/6⫹ primers (10 ), generating a 150-bp product; and one that detects C. trachomatis by use of primers specific to the
hsp60 gene of C. trachomatis (sense,
5⬘-GAT GGT GTT ACC GTT GCG
A-3⬘; antisense, 5⬘-TAA TAA TCG
TCT TTA ACA ACG T-3⬘), generating a truncated version (309 bp) of a
previously described product (13 ).
PCRs were also performed with the
MY09/11 and CTP1/2 primer sets
singly.
In the screened population, 21%
(21 of 100) of samples were positive
for HPV by the multiplex PCR (Table
1). The MY09/11 primers identified 3
other samples as HPV positive that
were not detected by the multiplex
assay (Table 1). Either the MY09/11
or the GP5⫹/6⫹ primers confirmed
all 21 of the samples positive by the
multiplex assay. Two samples were
positive for C. trachomatis in the multiplex assay (Table 1). These were
confirmed positive by the CTP1/2
and Hsp60 primers in single PCRs,
and no additional positive samples
were detected. A positive sample
was defined as positive by either the
multiplex or any of the single PCRs
for that organism. The sensitivity
and specificity of the multiplex with
respect to single PCR for the detection of HPV in the opportunistically
screened samples were 89% (95%
confidence interval, 70%–97%) and
100% (94%–100%; Table 1). The multiplex assay was 100% specific and
sensitive for the detection of C. trachomatis with respect to single PCR in
the screened population (Table 1).
To estimate the diagnostic sensitivity of the multiplex assay for the
detection of C. trachomatis, we performed multiplex PCR on 34 Preserv-
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Cyt fluid specimens from women
attending a genitourinary (GUM)
outpatient clinic who had tested positive for C. trachomatis by the LCx
(Abbott Laboratories). The sensitivity of the multiplex assay for the
detection of C. trachomatis in the
GUM clinic population was 100%
with respect to the commercial LCx
assay (Table 1). Ten of the 34 samples
were positive for HPV by the multiplex assay. These results were confirmed by single PCRs (Table 1). The
multiplex assay could detect as few
as 100 copies of the C. trachomatis
plasmid and 100 copies of the HPV
genome per microliter of extracted
DNA.
This is the first study looking at the
detection of both HPV and C. trachomatis from a single ThinPrep sample
by use of multiplex PCR. This simple
multiplex is rapid and could be used
to screen cervical ThinPrep samples
for both HPV and C. trachomatis, particularly in a high-risk population.
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Detection of Heavy Chain Disease by
Capillary Zone Electrophoresis

To the Editor:
Luraschi et al. (1 ) recently published
the first report describing the use of
capillary zone electrophoresis (CZE)
coupled with immunosubtraction to
detect and characterize low concentrations of free ␥ heavy chains in
serum. By contrast, we describe a
case in which CZE failed to detect
and characterize  heavy chain disease.
A 90-year-old woman who complained of weight loss presented
with progressive enlargement of the
left parotid gland, splenomegaly,
and palpable inguinal lymph node

